Managing Oral Anticoagulation Requires Expert Experience and Clinical Evidence
- Alex C. Spyropoulos
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The management of patients on chronic oral anticoagulant therapy, namely Vitamin K antagonists such as warfarin, is often associated with difficult and challenging issues for the healthcare practitioner. Many of these issues, such as warfarin failure or resistance, the optimal warfarin initiation dose, the optimal target International Normalized Ratio in antiphospholipid syndrome, the optimal monitoring frequency and use of point-of-care monitoring, the management of oral anticoagulation during invasive procedures, and the management of over-anticoagulation, have not been evaluated in rigorously-designed clinical trials. The latest American College of Chest Physician recommendations concerning these issues are Grade 2C, the weakest recommendations available. It remains up to the experience and expertise of the individual practitioner along with whatever clinical evidence is available in a particular healthcare environment—especially one associated with an anticoagulant management service—to implement management strategies with respect to these issues in patients on oral anticoagulation.
Supplementary Material (0)
- Guyatt G, Schunemann HJ, Cook D, Jaeschke R, Pauker S. Applying grades of recommendation for antithrombotic and thrombolytic therapy: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:179S–187S. CrossRef
- Spyropoulos AC, Hayth KA, Jenkins P. Anticoagulation with anisindione in a patient with a warfarin-induced skin reaction. Pharmacotherapy 2003;23(4):533–536.
- Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple-toe syndrome: infrequent complications of anticoagulant therapy. Thromb Haemost 1997;78:785–790.
- Owens JP, Mirtallo JM, Murphy CC. Oral anticoagulation in patients with short-bowel syndrome DICP 1990;24(6):585–589.
- Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in Vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005;93(1):23–26.
- Lefrere JJ, Guyon F, Horellon MH, Conard J, Samama M. Resistance to vitamin K antagonsists: 6 cases. Ann Med Interne 1986;137(5):384–390.
- Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and international normalized ratio: A retrospective analysis. J Clin Oncol 2000;8:3078–3083.
- Buller HR, Agnelli G, Hull RD, Hyers TM, Prins M, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:401S–428S. CrossRef
- Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–153.
- Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5 mg and 10 mg warfarin loading doses. Arch Intern Med 1999;159:46–48. CrossRef
- Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10 mg and 5 mg warfarin initiation nomograms together with low molecular weight heparin for outpatient treatment of acute venous thromboembolism. Ann Intern Med 2003;138:714–719.
- Ansell JE, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the Vitamin K antagonists: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:204S–233S. CrossRef
- Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133–1138. CrossRef
- Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:483S–512S. CrossRef
- Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5(3):S19–S24.
- Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995;155(20):2185–2189. CrossRef
- Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: A multi-site managed care study. Ann Pharmacother 2005;39:446–451.
- Spyropoulos AC. Perioperative bridging therapy for the at-risk patient on chronic anticoagulation. Dis Mon 2005;51(2):183–193.
- Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized trial. Lancet 2000;356:1551–1553. CrossRef
- Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg oral Vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol 2005;46(4):732–733. CrossRef
About this Article
- Managing Oral Anticoagulation Requires Expert Experience and Clinical Evidence
Journal of Thrombosis and Thrombolysis
Volume 21, Issue 1 , pp 91-94
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- oral anticoagulant therapy
- Vitamin K antagonist
- Industry Sectors
- Author Affiliations
- 1. Lovelace Sandia Health Systems, Clinical Thrombosis Center, 5400 Gibson Blvd SE, Albuquerque, NM, 87108